Shares of Aptevo Therapeutics Inc (NASDAQ:APVO) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a one year consensus price target of $6.00 for the company, according to Zacks. Zacks has also given Aptevo Therapeutics an industry rank of 199 out of 265 based on the ratings given to related companies.
Aptevo Therapeutics (NASDAQ:APVO) traded up $0.16 during trading hours on Thursday, hitting $3.38. The stock had a trading volume of 140,799 shares, compared to its average volume of 117,498. The company has a market cap of $74.51 and a P/E ratio of -1.86. The company has a current ratio of 7.76, a quick ratio of 7.67 and a debt-to-equity ratio of 0.19. Aptevo Therapeutics has a 1 year low of $1.15 and a 1 year high of $4.85.
TRADEMARK VIOLATION NOTICE: This report was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://sportsperspectives.com/2018/03/13/aptevo-therapeutics-inc-apvo-receives-average-rating-of-strong-buy-from-analysts.html.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.